Can Pharma Keep Pace With The Counterfeiters? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Can Pharma Keep Pace With The Counterfeiters?

Pharmaceutical Technology Europe
Volume 22, Issue 7

The full version of this counterfeiting feature can be read in the July issue of our digital magazine: http://www.pharmtech.com/ptedigital0710

The problem of counterfeit medicines was first addressed at an international level in 1985, when a conference of experts recommended that the World Health Organization (WHO), together with other international and non-governmental organisations, should study the feasibility of setting up a clearing house to collect data and to inform governments about the nature and extent of counterfeiting. Since then, however, the problem has only escalated. According to the WHO, the magnitude of the issue is difficult to assess because of the variety of information sources available.1 Additionally, the WHO stresses that counterfeiters are extremely flexible and can change their methods from day to day, so the results of a study may already be out of date the day they are released.


Jason Hosking/Getty Images
However, the statistics that are available show unsettling results. For example, compared with 2005, seizures of counterfeit medicines at the EU border increased by 380% in 2007.2 Meanwhile, research commissioned by Aegate revealed that 5% of consumers across five European countries suspect they may have received a counterfeit prescription drug.3 The research adds that the majority of consumers believe that the trade in counterfeit medicines is largely the responsibility of the manufacturer.

Fortunately, the threat of counterfeits has prompted the development of a number of anti-counterfeiting solutions, from simple holograms and watermarks, to sophisticated barcodes that enable track and trace, tagged packages, and even technologies that can be applied directly to individual tablets. But which solution is most widely used by the pharma industry?


Figure 1
To get a better idea, PTE conducted a survey4 of industry executives and found that, although barcoding and tamper-evident packaging was the most popular solution in use amongst those surveyed, astonishingly, the majority of respondents (27%) admitted that their company had yet to instate an anti-counterfeiting solution (Figure 1).

Products can never be made completely secure against counterfeiting; however, counterfeiters will always target medicines that are easiest to copy. In the EU, companies that have yet to implement a solution are going to have to move quickly in light of the significant threat that counterfeiting presents as well as amendments that are being made to the current EU anti-counterfeiting directive; one of which mandates safety features, such as seals or serial numbers, for certain medicines.5

Speaking to a variety of industry leaders, PTE examines some of the trends in anti-counterfeiting technologies, as well as the innovative solutions being used by the industry.

References

1. WHO, Medicines: counterfeit medicines, Fact sheet N275 (2010). http://www.who.int/

2. European Commission, Counterfeit Medicines (2010). http://ec.europa.eu/

3. Aegate, Medicines top counterfeit concern list in Europe — consumers call for tougher safety measures (2009). http://www.aegate.com/

4. http://www.pharmtech.com/counterfeitpoll

5. European Parliament, Fake medicines: MEPs want to target online sales (2010). http://www.europarl.europa.eu/

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here